Kither Biotech is a preclinical stage biopharma company focused on the development of therapies addressing unmet medical needs in pulmonary area, based on a strong PI3K expertise.

In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure.

Kither’s product portfolio also includes a molecule (CL27), that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma